Pieter Sonneveld, MD, PhD, Talks PERSEUS Trial Results

In this video interview with Blood Cancers Today, Dr. Sonneveld, a Professor of Hematology at Erasmus University in Rotterdam, the Netherlands, and President of the European Myeloma Network, discusses the results from the phase III PERSEUS trial.

The trial investigated patients who were transplantation eligible with newly diagnosed multiple myeloma and received either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group).

The results showed that the addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival in this group of patients, according to the New England Journal of Medicine article published on January 25, 2024.

“What we observed is a very good outcome after four years of follow-up, achieving the primary endpoints and also observing very good and deep responses,” he said. “This makes this regimen … the new standard of care for transplant-eligible patients with newly diagnosed myeloma.”

He also said that “there is no parallel in the literature” to these results so far, adding that in the future, “all the regiments will also be tested or are currently under investigation.”